Tremfya (guselkumab) / J&J, Otsuka, Novartis - LARVOL DELTA

Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis. (PubMed, BMJ Open Gastroenterol) - P2/3 | "This analysis of guselkumab in UC demonstrated changes in key pathways and cell types that are associated with achieving important clinical end points including HEMI at week 12."

Clinical • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept AFFINITY Study. (PubMed, Arthritis Rheumatol) - "Although the primary endpoint was not achieved, secondary endpoints and exploratory analyses suggest that participants with TNFi-IR PsA, particularly those with elevated CRP, could derive clinically meaningful benefits with guselkumab+golimumab combination therapy, with no new safety concerns, warranting further investigation."

Clinical • Journal • P2a data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Tuberculosis

A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD) (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

First-Line Guselkumab Combined with Exclusive Enteral Nutrition in Biologic-Naïve Young‑Onset Crohn's Disease: A Three-Case Series from China. (PubMed, J Inflamm Res) - "In this three-case real-world series from China, first‑line guselkumab plus EEN was associated with rapid short-term improvement across clinical, biochemical, endoscopic and imaging domains and was generally well tolerated. These observations are preliminary and hypothesis-generating and require confirmation in larger prospective cohorts."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Comparison of the Effects and Safety of Planned Limited-Time Withdrawal Versus Continuous Maintenance of Interleukin Inhibitors in Patients with Psoriasis: A Systematic Review and Network Meta-Analysis. (PubMed, Dermatol Ther (Heidelb)) - "Compared with continued treatment, planned withdrawal of anti-IL therapy is associated with a largely superior risk of relapse, without any reduction in the incidence of adverse events. Moreover, bimekizumab withdrawal demonstrated better outcomes than ixekizumab withdrawal did according to the PASI90 outcome."

Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis

Early respon se to guselkumab and biologic-naïve status predict sustained efficacy with extended dosing intervals in mild-to-moderate plaque psoriasis: A real-world retrospective study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Real-world evidence • Retrospective data • Dermatology • Immunology • Psoriasis

Guselkumab intervention and diet evaluation for pouchitis (clinicaltrialsregister.eu) - P4 | N=20 | Not yet recruiting | Sponsor: UZ Leuven

New P4 trial • Gastrointestinal Disorder • Inflammation

Clinical Outcomes of Guselkumab in Biologic-Naïve Psoriasis Patients with Short and Long Disease Durations: A Real-world Study in Taiwan (AAD 2026) - "Initiating guselkumab earlier showed higher responses, although the small sample sizes limited the robustness of these findings."

Clinical • Clinical data • Real-world • Real-world evidence • Dermatology • Immunology • Inflammation • Psoriasis

All that aches is not psoriatic arthritis: Recognizing the co-existence of psoriasis and rheumatoid arthritis (AAD 2026) - "TNF-α inhibitors and methotrexate were the most commonly used systemic treatments, used in 21(65.6%) and 20 (62.5%) patients, respectively. Other systemic agents used included leflunomide (43.7%), hydroxychloroquine (40.6%), sulfasalazine (31.2%), abatacept (25%), Janus kinase inhibitors (18.75%), and tocilizumab (9.37%)...Two patients required additional systemic therapy for treatment of their psoriasis and were treated with guselkumab and apremilast. Two patients experienced psoriasis exacerbation with adalimumab. Patients with psoriasis may have co-existing seropositive rheumatoid arthritis, which has important implications for evaluation and treatment distinctive from psoriatic arthritis. Joint symptoms should prompt evaluation and consideration of a rheumatology referral, as treating rheumatoid arthritis can also improve psoriasis."

Dermatology • Immunology • Inflammatory Arthritis • Pain • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy of Biologics and Small Molecules for Pediatric Plaque Psoriasis: A Systematic Review of Randomized Control Trials (AAD 2026) - "Systemic therapies evaluated were apremilast (22.1%, 163/738), etanercept (19.9%, 147/738), secukinumab (16.5%, 122/738), ixekizumab (15.6%, 115/738), adalimumab (10.4%, 77/738), ustekinumab (9.9%, 73/738), and guselkumab (5.6%, 41/738). No treatment-related deaths were reported. Our results indicate that interleukin-17 inhibitors, particularly secukinumab and ixekizumab, achieve the highest efficacy in pediatric plaque psoriasis with favorable short-term safety profiles."

Clinical • Review • Dermatology • Immunology • Infectious Disease • Inflammation • Pediatrics • Psoriasis • IL17A

VISIBLE Cohort A: Guselkumab Skin Clearance and Patient-Reported Outcomes Across Skin and Joint Symptoms Through Week 100 in Participants With Moderate-to-Severe Plaque Psoriasis Across All Skin Tones (AAD 2026) - "Results demonstrate guselkumab’s durable effect on moderate-to-severe plaque psoriasis and improvement of PsA symptoms across participants of all skin tones based on clinician-/patient-reported outcomes."

Clinical • Patient reported outcomes • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

Effects of interleukin-23 inhibitors on carotid intima-media thickness in patients with psoriasis (AAD 2026) - "Twelve patients were recruited (7 on risankizumab, 3 on guselkumab, and 2 on tildrakizumab), with a mean age of 53 ± 7.1 years, a mean PASI of 7 ± 5.2, a mean BMI of 29.9 ± 4, an average of 1.6 ± 1 prior biologic therapies, and a mean baseline cIMT of 0.78 ± 0.19 mm. These results suggest that IL-23 inhibitors may reduce cIMT and total cholesterol in patients with psoriasis, potentially lowering CVR. Larger studies with longer follow-up are required to validate these results."

Clinical • Cardiovascular • Dermatology • Immunology • Inflammation • Psoriasis • IL23A

Guselkumab Re-Treatment After Withdrawal: Rapid Regain of Disease Control in Super-Responders With Moderate-to-Severe Plaque Psoriasis - Final Week 220 Phase 3b GUIDE Findings (AAD 2026) - "Through 3 years post-guselkumab withdrawal, SRes remained treatment-free for an extended period. The majority of SRes who lost response, regained disease control within ~8W after one guselkumab dose, with similar outcomes across subgroups. These findings support the durability of guselkumab response and effectiveness of re-treatment, demonstrating long-term disease control and sustained reduction in disease burden."

P3 data • Dermatology • Immunology • Psoriasis

Patient-Level Persistence of On-Treatment Remission With Guselkumab: Pooled Results From VOYAGE 1 and VOYAGE 2 Participants With Moderate-to-Severe Plaque Psoriasis (AAD 2026) - "Among participants with moderate-to-severe PsO, guselkumab provided highly durable on-treatment PsO remission through 5 years."

Clinical • Dermatology • Immunology • Psoriasis

Representation of Race and Ethnicity in Randomized Control Trials of Biologic Therapies for Psoriasis: A Scoping Review (AAD 2026) - " Following Joanna Briggs Institute methodology, we searched MEDLINE (PubMed), Embase (Elsevier), and Cochrane Library in June 2024 for RCTs evaluating efficacy and/or safety of adalimumab, infliximab, etanercept, bimekizumab, ustekinumab, and guselkumab. Black and Hispanic patients remain underrepresented in psoriasis biologic RCTs despite higher disease burden, and demographic reporting is inconsistent, limiting generalizability. Trials documenting race/ethnicity appeared in higher impact, more frequently cited journals. Future biologic trials should prioritize diverse recruitment and standardized demographic reporting to strengthen equity and applicability of findings."

Clinical • Review • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry. (AAD 2026) - " We analyzed crude incidence rates of overall, serious, recurrent, and infections of special interest in patients treated with etanercept, infliximab, certolizumab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab, apremilast, and dimethyl fumarate. Modern systemic therapies for psoriasis show a favorable infection safety profile in real-world settings. IL-17 inhibitors appear to increase the risk of Candida infections, while some biologics may reduce the incidence of respiratory and viral infections."

Clinical • Candidiasis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • IL17A

Beyond Trial-and-Error: Mechanism-Guided Use of Biologics in Scalp Psoriasis (AAD 2026) - "Ustekinumab offered modest scalp improvement but lacked dedicated trials. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) consistently produced the most rapid clearance, with several maintaining high rates of complete response in long-term follow-up. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) provided excellent durability, with real-world evidence confirming sustained clearance. No scalp-specific outcomes were reported for certolizumab... Biologic selection in scalp psoriasis can move beyond trial-and-error toward mechanism-guided therapy. IL-17 inhibitors are best suited for rapid scalp clearance, while IL-23 inhibitors may optimize long-term durability. These findings support the development of a practical, scalp-specific treatment algorithm to address one of the most visible and burdensome manifestations of psoriasis."

Dermatology • Immunology • Psoriasis • CD8 • IL22 • IL23A

APEX: Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis by Participant Baseline Characteristics (AAD 2026) - "Improvements across endpoints were consistent in guselkumab-treated subgroups defined by sex, BMI, PsA disease characteristics, and concomitant methotrexate use. In biologic-naïve patients with active, erosive PsA, guselkumab provided significantly greater joint and skin improvements versus placebo at W24 and is the only interleukin-23 inhibitor shown to provide significant inhibition of structural damage progression. Treatment effects were generally consistent across subgroups defined by baseline characteristics and key radiographic features."

Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP

Guselkumab shows better long-term effectiveness and drug survival compared to secukinumab through 84 weeks in patients with moderate-to-severe plaque psoriasis - Results from the German non-interventional G-REAL study (AAD 2026) - "The probabilities of drug survival at 18 months for GUS were: 84.4% (overall) and 87.1% (bn); for SEC were: 72.5% (overall) and 78.9% (bn). Conclusion Guselkumab demonstrated substantially higher rates of complete skin clearance and better drug-survival, especially in bio-naïve patients, compared to secukinumab through 84 weeks in real-world practice, indicating improved benefits with first-line use of guselkumab."

Clinical • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Enhanced effectiveness of guselkumab as first-line biologic therapy in psoriasis: real-world results over 84 weeks from the G-REAL study (AAD 2026) - "Introduction The prospective, non-interventional G-REAL study evaluates real-world effectiveness of guselkumab (GUS), a p19 subunit-targeted IL-23 inhibitor, versus secukinumab, an IL-17A inhibitor, across treatment lines in patients with moderate-to-severe psoriasis in Germany. Conclusion Guselkumab demonstrated robust long-term effectiveness, drug survival, and improvements in quality of life across treatment lines over 84 weeks in psoriasis patients in real-world practice. First-line use of guselkumab provided additional benefits in achieving complete skin clearance."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A • IL23A

SPECTREM: Guselkumab Skin Clearance and Patient-Reported Outcome Results Across Skin and Joint Symptoms Through Week 48 in Low Body Surface Area, Moderate Plaque Psoriasis With at Least One Moderate High-Impact Site Involved (AAD 2026) - "Consistent improvements across clinician-evaluated skin clearance and skin/joint PRO measures, including meaningful reductions in PsA symptoms, substantiate guselkumab’s effectiveness in patients with low BSA, moderate psoriasis with high-impact site involvement."

Clinical • Patient reported outcomes • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators (AAD 2026) - "The immunomodulatory agents assessed included Adalimumab, Infliximab, Ixekizumab, Secukinumab, Tildrakizumab, Certolizumab pegol, Risankizumab, Etanercept, Guselkumab, and Ustekinumab. Inhibition of this inflammation by immunomodulators could impede PsA progression. Physicians can consider Risankizumab, Guselkumab, and Ustekinumab as treatment options for PsO patients with PsA risk factors to mitigate disease progression and improve patients’ quality of life."

Clinical • Immunomodulating • Cardiovascular • Dermatology • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Gout • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A • JAK1 • JAK3 • TNFA

Long-Term Real-World Effectiveness, Safety and Retention of Guselkumab in a Spanish Psoriasis Cohort: A Retrospective Study (AAD 2026) - "A majority (75%) had been treated with 3 or more prior systemic therapies, such as methotrexate (77.5%), adalimumab (62.5%), ustekinumab (57.5%) and secukinumab (27.5%). The best outcomes were observed in patients with plaque psoriasis phenotype and without palmoplantar or joint involvement. Our findings further suport guselkumab as a leading therapeutic option for moderate-to-severe plaque psoriasis in real clinical practice."

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

Biologic treatment in Psoriasis and Hidradenitis Suppurativa patients with active malignancy: Experience from a Tertiary Care Hospital. (AAD 2026) - "Three patients were on adalimumab at cancer diagnosis; all switched to a different biologic class afterward. Biologic agents used included ustekinumab (n=1), tildrakizumab (n=4), guselkumab (n=1), and risankizumab (n=3)...This patient was not eligible for curative treatment, received palliative care, and died during follow-up. To sum up, biologic therapy may be feasible in selected patients with recent malignancy under close monitoring, preferring IL-23 inhibitors due to their safety profile."

Clinical • Colorectal Adenocarcinoma • Colorectal Cancer • Dermatology • Hidradenitis Suppurativa • Immunology • Lung Adenocarcinoma • Lung Cancer • Oncology • Palliative care • Prostate Adenocarcinoma • Prostate Cancer • Psoriasis • Solid Tumor • Squamous Cell Carcinoma • Supraglottic Laryngeal Cancer • IL23A